Research from the University of California, Berkeley, highlights a promising oral compound, TOFA, capable of inducing significant weight loss in obese mice. Unlike appetite suppressants, TOFA enhances energy expenditure according to findings in Science Advances.
The TOFA molecule led to an 18% average reduction in body weight in mice without affecting their food intake or causing significant loss of lean mass.
Potential Benefits Over Current Treatments
Common weight-loss drugs, like semaglutide, often reduce food intake but can cause gastrointestinal issues and muscle loss. Patients also frequently regain weight after stopping these medications. TOFA, operating within cells, blocks enzymes that produce lipids and activates genes for fat burning and energy production.
Dr. Leslie Pristas, a bariatric surgeon, stresses the importance of maintaining muscle mass during weight loss, as it supports daily function and combats aging. TOFA-treated mice increased energy expenditure under normal conditions without decreased activity or dangerous temperature rises.
Combining Treatments
Pairing TOFA with drugs like semaglutide or tirzepatide resulted in greater body weight reduction and improvements in blood sugar, insulin, and triglyceride levels than either drug alone. Post-treatment, mice treated with TOFA kept body weight similar to control levels, whereas semaglutide-treated mice regained weight rapidly.
“Obesity is super complex,” Dr. Pristas explains. “There’s not just one mechanism for weight gain.”
The complexity means that one solution often doesn’t fit all. Stopping medication can lead to weight regain due to the body’s perceived weight set point.
Additional Health Benefits
TOFA also showed potential in addressing metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. Mice receiving TOFA had reduced liver fat, inflammation, and fibrosis.
Unlike some similar drugs, TOFA did not raise blood triglyceride levels, thus avoiding potential cardiovascular risks.
Research Limitations
All experiments used male mice; researchers need to verify results in female animals. TOFA has yet to undergo human trials, so optimal dosing and safety over extended periods remain uncertain.
Dr. Pristas advises cautious optimism regarding mouse data, warning of possible unforeseen side effects in humans. “If it sounds too good to be true, it’s probably too good to be true,” she cautions.
Despite these uncertainties, TOFA holds potential for standalone use or as part of a combination therapy in the future. Researchers associated with the study have connections to ReRx Therapeutics, a company with development rights for the discovery.